DOE Invests $263M in Janesville Fusion Facility to Revolutionize Medical Isotope Production

The Chrysalis facility aims to secure a reliable supply of crucial cancer and heart disease diagnostics for American patients.

Apr. 10, 2026 at 4:08am

Got story updates? Submit your updates here. ›

A highly structured abstract painting featuring sweeping geometric arcs, concentric circles, and precise botanical spirals in earthy tones of green, brown, and blue, conceptually representing the complex fusion and fission processes used to produce critical medical isotopes at the Chrysalis facility.The Chrysalis facility's advanced fusion-fission technology promises to revolutionize domestic medical isotope production, bolstering America's healthcare security.Janesville Today

The U.S. Department of Energy has committed $263 million to SHINE Technologies' Chrysalis facility in Janesville, Wisconsin, a project that will utilize fusion and fission technologies to produce essential medical isotopes like molybdenum-99 and technetium-99m. This investment marks a significant milestone in advancing nuclear technology and reducing the country's reliance on foreign imports of these critical healthcare resources.

Why it matters

The Chrysalis facility's dual-technology approach promises to revolutionize medical isotope production, ensuring a steady supply for American patients and reducing the U.S. healthcare system's vulnerability to supply chain disruptions. This strategic investment by the DOE aligns with broader goals of energy dominance and national security, as it aims to on-shore critical production and foster a strong next-generation nuclear workforce.

The details

The Chrysalis facility is designed to be the world's largest medical isotope producer, capable of withstanding extreme conditions like airplane crashes and F5 tornadoes. By utilizing both fusion and fission technologies, the facility will be able to produce crucial isotopes for cancer screenings and heart disease diagnostics, potentially ending the reliance on foreign imports of molybdenum-99.

  • The DOE's $263 million conditional loan to SHINE Technologies was announced in April 2026.
  • The Chrysalis facility is expected to become operational in 2028.

The players

SHINE Technologies

A company developing advanced nuclear technology, including the Chrysalis facility in Janesville, Wisconsin.

U.S. Department of Energy (DOE)

The federal agency that has committed $263 million in funding to the Chrysalis facility, a strategic investment in securing a reliable supply of medical isotopes for the United States.

Gregory Beard

The director of the DOE's Office of Energy Dominance Financing, who emphasizes the project's role in improving the nuclear supply chain and fostering a strong next-generation nuclear workforce.

Got photos? Submit your photos here. ›

What they’re saying

“This investment is not just about funding; it's about securing a critical piece of America's healthcare infrastructure.”

— The author

“This project is a testament to the DOE's commitment to innovation and national security, especially in the realm of healthcare.”

— The author

“This investment aligns with the DOE's broader goals of energy dominance and national security.”

— The author

What’s next

The Chrysalis facility is expected to become operational in 2028, marking a significant milestone in the production of crucial medical isotopes for the United States.

The takeaway

The DOE's investment in the Chrysalis facility represents a strategic move to secure a reliable supply of medical isotopes, reduce the country's reliance on foreign imports, and foster innovation in the nuclear technology sector. This project has the potential to revolutionize healthcare diagnostics and treatment, while also strengthening national security and energy dominance.